SU9518

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H561270

CAS#: 251356-32-8

Description: SU9518 is a tyrosine kinase inhibitor with PDGFRα specificity. SU9518 can inhibit the development of proliferative vitreoretinopathy (PVR) in fibroblast and Müller cell rabbit models.


Chemical Structure

img
SU9518
CAS# 251356-32-8

Theoretical Analysis

Hodoodo Cat#: H561270
Name: SU9518
CAS#: 251356-32-8
Chemical Formula: C18H17BrN2O3
Exact Mass: 388.04
Molecular Weight: 389.250
Elemental Analysis: C, 55.54; H, 4.40; Br, 20.53; N, 7.20; O, 12.33

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: SU9518; SU 9518; SU-9518; 5-Br-SU6668; 5 Br SU6668; 5BrSU6668

IUPAC/Chemical Name: 3-[5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrol-3-yl]propionic acid

InChi Key: CQXPYMNBBOWLME-ZSOIEALJSA-N

InChi Code: InChI=1S/C18H17BrN2O3/c1-9-12(4-6-17(22)23)10(2)20-16(9)8-14-13-7-11(19)3-5-15(13)21-18(14)24/h3,5,7-8,20H,4,6H2,1-2H3,(H,21,24)(H,22,23)/b14-8-

SMILES Code: O=C(O)CCC1=C(C)NC(/C=C2C(NC3=C\2C=C(Br)C=C3)=O)=C1C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 389.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Velez G, Weingarden AR, Lei H, Kazlauskas A, Gao G. SU9518 inhibits proliferative vitreoretinopathy in fibroblast and genetically modified Müller cell-induced rabbit models. Invest Ophthalmol Vis Sci. 2013 Feb 19;54(2):1392-7. doi: 10.1167/iovs.12-10320. PubMed PMID: 23341018; PubMed Central PMCID: PMC3597189.

2: Li M, Ping G, Plathow C, Trinh T, Lipson KE, Hauser K, Krempien R, Debus J, Abdollahi A, Huber PE. Small molecule receptor tyrosine kinase inhibitor of platelet-derived growth factor signaling (SU9518) modifies radiation response in fibroblasts and endothelial cells. BMC Cancer. 2006 Mar 24;6:79. PubMed PMID: 16556328; PubMed Central PMCID: PMC1458351.

3: Dadrich M, Nicolay NH, Flechsig P, Bickelhaupt S, Hoeltgen L, Roeder F, Hauser K, Tietz A, Jenne J, Lopez R, Roehrich M, Wirkner U, Lahn M, Huber PE. Combined inhibition of TGFβ and PDGF signaling attenuates radiation-induced pulmonary fibrosis. Oncoimmunology. 2015 Dec 29;5(5):e1123366. doi: 10.1080/2162402X.2015.1123366. eCollection 2016 May. PubMed PMID: 27467922; PubMed Central PMCID: PMC4910723.

4: Yamasaki Y, Miyoshi K, Oda N, Watanabe M, Miyake H, Chan J, Wang X, Sun L, Tang C, McMahon G, Lipson KE. Weekly dosing with the platelet-derived growth factor receptor tyrosine kinase inhibitor SU9518 significantly inhibits arterial stenosis. Circ Res. 2001 Mar 30;88(6):630-6. PubMed PMID: 11282898.

5: Villalta SA, Lang J, Kubeck S, Kabre B, Szot GL, Calderon B, Wasserfall C, Atkinson MA, Brekken RA, Pullen N, Arch RH, Bluestone JA. Inhibition of VEGFR-2 reverses type 1 diabetes in NOD mice by abrogating insulitis and restoring islet function. Diabetes. 2013 Aug;62(8):2870-8. doi: 10.2337/db12-1619. Epub 2013 Jul 8. PubMed PMID: 23835340; PubMed Central PMCID: PMC3717875.

6: Abdollahi A, Li M, Ping G, Plathow C, Domhan S, Kiessling F, Lee LB, McMahon G, Gröne HJ, Lipson KE, Huber PE. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med. 2005 Mar 21;201(6):925-35. PubMed PMID: 15781583; PubMed Central PMCID: PMC2213091.